Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Brazil
· Delayed Price · Currency is BRL 2.160
+0.030 (1.41%)
At close: Dec 5, 2025
BVMF:ONCO3 Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 5,937 | 6,227 | 5,489 | 4,088 | 2,702 | 2,035 | Upgrade
|
| Revenue Growth (YoY) | -2.61% | 13.45% | 34.26% | 51.30% | 32.77% | 20.46% | Upgrade
|
| Cost of Revenue | 4,128 | 4,167 | 3,560 | 2,636 | 1,833 | 1,400 | Upgrade
|
| Gross Profit | 1,808 | 2,060 | 1,929 | 1,452 | 868.79 | 635.68 | Upgrade
|
| Selling, General & Admin | 1,408 | 1,397 | 1,172 | 980.82 | 688.05 | 603.61 | Upgrade
|
| Other Operating Expenses | 2,425 | 775.7 | -13.16 | 0.19 | 3.53 | 12.45 | Upgrade
|
| Operating Expenses | 3,833 | 2,172 | 1,159 | 981.01 | 691.58 | 616.06 | Upgrade
|
| Operating Income | -2,024 | -112.05 | 769.67 | 471.1 | 177.22 | 19.62 | Upgrade
|
| Interest Expense | -695.29 | -613.5 | -588.3 | -490.11 | -154.36 | -94.8 | Upgrade
|
| Interest & Investment Income | 301.65 | 248.21 | 105.54 | 141.08 | 54.41 | 21.93 | Upgrade
|
| Earnings From Equity Investments | -3.83 | -7.9 | -11.65 | -0.54 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2.9 | -29 | 7.92 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -136.19 | -127.86 | 33.78 | - | -10.98 | - | Upgrade
|
| EBT Excluding Unusual Items | -2,555 | -642.09 | 316.95 | 121.54 | 66.29 | -53.26 | Upgrade
|
| Legal Settlements | -20.29 | -14.77 | -14.43 | - | -3.95 | - | Upgrade
|
| Pretax Income | -2,792 | -656.86 | 302.52 | 121.54 | 62.34 | -53.26 | Upgrade
|
| Income Tax Expense | 121.78 | 60.57 | -10.04 | 7.77 | 84.75 | 68.09 | Upgrade
|
| Earnings From Continuing Operations | -2,914 | -717.43 | 312.56 | 113.77 | -22.42 | -121.34 | Upgrade
|
| Minority Interest in Earnings | 101.21 | 71.24 | -88.94 | -67.51 | -24.48 | -36.35 | Upgrade
|
| Net Income | -2,813 | -646.19 | 223.62 | 46.26 | -46.9 | -157.69 | Upgrade
|
| Net Income to Common | -2,813 | -646.19 | 223.62 | 46.26 | -46.9 | -157.69 | Upgrade
|
| Net Income Growth | - | - | 383.39% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 652 | 616 | 524 | 480 | 412 | 402 | Upgrade
|
| Shares Outstanding (Diluted) | 652 | 616 | 536 | 532 | 412 | 402 | Upgrade
|
| Shares Change (YoY) | 10.99% | 15.09% | 0.72% | 28.93% | 2.65% | 0.29% | Upgrade
|
| EPS (Basic) | -4.31 | -1.05 | 0.43 | 0.10 | -0.11 | -0.39 | Upgrade
|
| EPS (Diluted) | -4.31 | -1.05 | 0.42 | 0.09 | -0.11 | -0.39 | Upgrade
|
| EPS Growth | - | - | 379.95% | - | - | - | Upgrade
|
| Free Cash Flow | -506.41 | -399.1 | -363.26 | -571.82 | -211.23 | -19.24 | Upgrade
|
| Free Cash Flow Per Share | -0.78 | -0.65 | -0.68 | -1.07 | -0.51 | -0.05 | Upgrade
|
| Gross Margin | 30.46% | 33.09% | 35.14% | 35.52% | 32.15% | 31.23% | Upgrade
|
| Operating Margin | -34.10% | -1.80% | 14.02% | 11.52% | 6.56% | 0.96% | Upgrade
|
| Profit Margin | -47.38% | -10.38% | 4.07% | 1.13% | -1.74% | -7.75% | Upgrade
|
| Free Cash Flow Margin | -8.53% | -6.41% | -6.62% | -13.99% | -7.82% | -0.95% | Upgrade
|
| EBITDA | -1,835 | 78.61 | 931.27 | 646.25 | 270.2 | 126.43 | Upgrade
|
| EBITDA Margin | -30.91% | 1.26% | 16.97% | 15.81% | 10.00% | 6.21% | Upgrade
|
| D&A For EBITDA | 189.08 | 190.65 | 161.6 | 175.15 | 92.99 | 106.81 | Upgrade
|
| EBIT | -2,024 | -112.05 | 769.67 | 471.1 | 177.22 | 19.62 | Upgrade
|
| EBIT Margin | -34.10% | -1.80% | 14.02% | 11.52% | 6.56% | 0.96% | Upgrade
|
| Effective Tax Rate | - | - | - | 6.39% | 135.96% | - | Upgrade
|
| Revenue as Reported | 6,227 | 6,227 | 5,489 | 4,088 | 2,702 | 2,035 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.